Treating patients infected with the SARS-CoV-2 Omicron variant with a traditional Chinese medicine, Shufeng Jiedu capsule

Zhang, Jing; Liu, Huan; Zhang, Guoliang; Li, Mingqiang; Ma, Bitao; Yang, Weidong

doi:10.5582/bst.2022.01220

Cited by 15 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Afterward, we read the full-texts of 22 articles (Supplementary Table 2). Totally 10 articles were eligible for inclusion, while 9 articles (25)(26)(27)(28)(29)(30)(31)(32)(33) were enrolled for finally analysis, since one study (34) reported no specific value of the outcome, causing inability to merge data. The literature screening procedure is displayed in Figure 1.…”

Section: Results Study Screeningmentioning

confidence: 99%

“…Table 2 displays risk of bias of the enrolled RCTs (25,33). Two studies describe the generation process of an appropriate random sequence, with "generation of random sequence" being considered to be of "low risk."…”

Section: Risk Of Bias and Methodological Quality Assessmentmentioning

confidence: 99%

“…There were no missing data in either study and this work considered "incomplete outcome data" to be of "low risk." Regarding blinding of participants and outcome reviewers, one study (33) was randomized open-label and rated as "high risk, " while the other (25) was not reported in the original text and was therefore "unclear risk." Additionally, allocation concealment method, selective report of outcomes, and other biases were not reported in two articles, which were thus rated as "unclear risk.…”

Section: Risk Of Bias and Methodological Quality Assessmentmentioning

confidence: 99%

“…Totally 10 studies were included, and were published from 2020 to 2022 with 3 in English and 7 in Chinese. Specifically, two studies was RCTs (25,33), one study was a non-RCT (26), five were retrospective cohort studies (28)(29)(30)(31)(32), and two were case series studies (27,34). Additionally, a total of 1,083 patients were involved in the study, and the sample size of each study ranged from 11 to 234 cases, with an average sample size of 108 cases.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…The results of a RCT (33) and a cohort study (30) revealed that adding SFJD on the basis of WM could reduce the rate Meta-analysis of nucleic acid conversion rate in the SFJD + WM group vs. the WM group in COVID-19 patients. of turning to severe/critical illness, but the difference had no statistical significance between the SFJD + WM and the WM group (RR = 0.14, 95%CI: 0.01-2.74, P = 0.20, RCT) (RR = 0.33, 95%CI: 0.10-1.13, P = 0.08, cohort study) (Table 4).…”

Section: The Rate Of Turning To Severe/critical Illnessmentioning

confidence: 99%

See 4 more Smart Citations

The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

IntroductionShufeng Jiedu capsule (SFJD) is a commonly used Chinese patent medicine in China. Some studies have reported that SFJD has therapeutic effects in patients diagnosed with COVID-19. This systematic review aimed to critically evaluate the efficacy and safety of SFJD combined with western medicine (WM) for treating COVID-19.MethodsA literature search by using WHO COVID-19 database, PubMed, Embase, Cochrane Library, the Web of Science, CKNI, Wanfang, VIP, SinoMed, and clinical trial registries was conducted, up to 1 August 2022. Randomized controlled trials (RCTs), non-RCTs, cohort studies and case series of SFJD combined with WM for COVID-19 were included. Literature screening, data extraction, and quality assessment were performed independently by two reviewers in line with the same criteria. We used the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) to assess the certainty of evidence. Meta-analyses were performed with Revman 5.3 if possible. The descriptive analysis was conducted when the studies could not be meta-analyzed.ResultsTotally 10 studies with 1,083 patients were included. Their methodological quality were moderate. The results demonstrated that compared to WM group, SFJD + WM group remarkably increased the nucleic acid negative conversion rate (RR = 1.40, 95%CI: 1.07–1.84), total effective rate (RR = 1.18, 95%CI: 1.07–1.31), cure rate (RR = 4.06, 95%CI: 2.19–7.53), and the chest CT improvement rate (RR = 1.19, 95%CI: 1.08–1.31), shorten nucleic acid negative conversion time (MD = −0.70, 95%CI: −1.14 to −0.26), reduced the clinical symptom disappearance time (fever, diarrhea, cough, fatigue, pharyngalgia, nasal congestion, and rhinorrhea), as well as improved the levels of laboratory outcomes (CRP, IL-6, Lym, and Neu). Additionally, the incidence of adverse reactions did not exhibit any statistically significant difference between SFJD + WM group and WM group.ConclusionSFJD combined with WM seems more effective than WM alone for the treatment of COVID-19. However, more well-designed RCTs still are warranted.Systematic review registration[https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022306307].

show abstract

Section: Results Study Screeningmentioning

confidence: 99%

Section: Risk Of Bias and Methodological Quality Assessmentmentioning

confidence: 99%

Section: Risk Of Bias and Methodological Quality Assessmentmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: The Rate Of Turning To Severe/critical Illnessmentioning

confidence: 99%

See 3 more Smart Citations

The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

A novel multi-view contrastive learning for herb recommendation

Yang,

Cheng,

Kang

et al. 2024

Appl Intell

View full text Add to dashboard Cite

Efficacy and Safety of Huashi Baidu Granules in Treating Patients with SARS-CoV-2 Omicron Variant: A Single-Center Retrospective Cohort Study

Chen

Zhang

et al. 2023

Chin. J. Integr. Med.

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of Huashi Baidu Granules (HSBD) in treating patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. Methods A single-center retrospective cohort study was conducted during COVID-19 Omicron epidemic in the Mobile Cabin Hospital of Shanghai New International Expo Center from April 1st to May 23rd, 2022. All COVID-19 patients with asymptomatic or mild infection were assigned to the treatment group (HSBD users) and the control group (non-HSBD users). After propensity score matching in a 1:1 ratio, 496 HSBD users of treatment group were matched by propensity score to 496 non-HSBD users. Patients in the treatment group were administrated HSBD (5 g/bag) orally for 1 bag twice a day for 7 consecutive days. Patients in the control group received standard care and routine treatment. The primary outcomes were the negative conversion time of nucleic acid and negative conversion rate at day 7. Secondary outcomes included the hospitalized days, the time of the first nucleic acid negative conversion, and new-onset symptoms in asymptomatic patients. Adverse events (AEs) that occurred during the study were recorded. Further subgroup analysis was conducted in vaccinated (378 HSBD users and 390 non-HSBD users) and unvaccinated patients (118 HSBD users and 106 non-HSBD users). Results The median negative conversion time of nucleic acid in the treatment group was significantly shortened than the control group [3 days (IQR: 2–5 days) vs. 5 days (IQR: 4–6 days); P <0.01]. The negative conversion rate of nucleic acid in the treatment group were significantly higher than those in the control group at day 7 (91.73% vs. 86.90%, P =0.014). Compared with the control group, the hospitalized days in the treatment group were significantly reduced [10 days (IQR: 8–11 days) vs. 11 days (IQR: 10.25–12 days); P <0.01]. The time of the first nucleic acid negative conversion had significant differences between the treatment and control groups [3 days (IQR: 2–4 days) vs. 5 days (IQR: 4–6 days); P <0.01]. The incidence of new-onset symptoms including cough, pharyngalgia, expectoration and fever in the treatment group were lower than the control group ( P <0.05 or P <0.01). In the vaccinated patients, the median negative conversion time and hospitalized days were significantly shorter than the control group after HSDB treatment [3 days (IQR: 2–5 days) vs. 5 days (IQR: 4–6 days), P <0.01; 10 days (IQR: 8–11 days) vs. 11 days (IQR: 10–12 days), P <0.01]. In the unvaccinated patients, HSBD treatment efficiently shorten the median...

show abstract

Treating patients infected with the SARS-CoV-2 Omicron variant with a traditional Chinese medicine, Shufeng Jiedu capsule

Cited by 15 publications

References 12 publications

The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis

The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis

A novel multi-view contrastive learning for herb recommendation

Efficacy and Safety of Huashi Baidu Granules in Treating Patients with SARS-CoV-2 Omicron Variant: A Single-Center Retrospective Cohort Study

Contact Info

Product

Resources

About